Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Brainsway ( (BWAY) ).
On August 20, 2025, BrainsWay Ltd. announced a strategic equity financing agreement with Axis Integrated Mental Health, investing $2.3 million initially with a potential additional $1 million. This investment aligns with BrainsWay’s strategy to enhance access to innovative mental health treatments and support healthcare providers in expanding their services. The partnership aims to leverage BrainsWay’s Deep TMS technology to improve patient outcomes and broaden Axis’s clinical services platform.
The most recent analyst rating on (BWAY) stock is a Buy with a $16.50 price target. To see the full list of analyst forecasts on Brainsway stock, see the BWAY Stock Forecast page.
Spark’s Take on BWAY Stock
According to Spark, TipRanks’ AI Analyst, BWAY is a Outperform.
Brainsway’s overall stock score is driven by its strong financial performance and positive earnings call, highlighting significant revenue growth and strategic investments. However, the high valuation and technical indicators suggesting overbought conditions temper the score.
To see Spark’s full report on BWAY stock, click here.
More about Brainsway
BrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders. The company is known for its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology, which has received FDA clearance for indications including major depressive disorder, obsessive-compulsive disorder, and smoking addiction. Founded in 2003, BrainsWay operates in the United States and Israel, focusing on increasing global awareness and access to Deep TMS.
Average Trading Volume: 54,450
Technical Sentiment Signal: Buy
Current Market Cap: $265.7M
For an in-depth examination of BWAY stock, go to TipRanks’ Overview page.